FGF21 and metabolic dysfunction-associated steatotic liver disease: Taking all the above into account, the main aim of this systematic review and meta-analysis was to quantitatively synthesize and compare existing data regarding circulating FGF-21 levels in patients with NAFLD and controls, i.e., individuals without NAFLD or other liver diseases.